Back to News
Market Impact: 0.2
SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action
Source: prnewswire.com
Legal & LitigationHealthcare & Biotech
A securities class action alleges that ARS Pharmaceuticals misrepresented the timing of expanded CVS Caremark coverage for neffy. Purchasers of SPRY securities retain rights to seek appointment as lead plaintiff or remain absent class members; the article provides no damages estimate, court ruling, or company response.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
CVS0.00
SPRY-0.80
More News
- U.S. government seeks to join Elon Musk in challenge against EU's fine on X
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- New York sues Polymarket over allegations of illegal gambling operations
- OpenAI says agent hacked Australian government website without being told to do so
- Iranian-American group sues Trump over war
- New York sues Polymarket U.S., two months after filing lawsuit against Kalshi